Delstrigo (Doravirine/Lamivu/Tenofov Diso) Patent Expiration, LOE Window & CMS Spending
Delstrigo (Doravirine/Lamivu/Tenofov Diso) by Merck & Co.: FDA Orange Book core substance LOE 2032-08-30 (last listed 2036-11-29), 0 AB generics, $34.8M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Merck & Co. |
| FDA Application & Pathway | N210807 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2032-08-30 |
| Last Listed Patent or Exclusivity Date | 2036-11-29 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $34.8M |
| 2024 Medicare Part D Spend | $18.5M |
| 2024 Medicaid Spend | $16.3M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.